The global diabetic retinopathy market size reached US$ 8.1 Billion in 2023. Looking forward, the market is projected to reach US$ 13.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.40% during 2023-2032. The surging prevalence of diabetes, rising demand for effective treatments, and growing awareness regarding early diagnosis and treatment of diabetic retinopathy represent some of the key factors driving the market.
Diabetic retinopathy (DR) is a common complication of diabetes that affects the retina, the part of the eye that senses light and sends signals to the brain. It occurs when high blood sugar levels damage the small blood vessels in the retina, causing them to leak or become blocked. This can lead to vision loss or blindness if left untreated. There are two main types of diabetic retinopathy, namely non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Its diagnosis involves a comprehensive eye exam, which may include tests such as fluorescein angiography and optical coherence tomography. These tests can help to identify the presence and severity of DR, allowing for early intervention and treatment.
Currently, there are several treatment options available for DR, including the use of intraocular steroid injections, laser treatment, and vitrectomy. Intraocular steroid injections can help to reduce inflammation and swelling in the eye, while laser treatment can be used to seal leaking blood vessels and prevent further damage to the retina. In more severe cases, a vitrectomy may be necessary to remove blood or scar tissue from the eye.
The rising demand for effective treatments due to the growing awareness of diabetic retinopathy and its potential consequences is acting as another growth-inducing factor. Furthermore, the surging awareness regarding early diagnosis and treatment of diabetic retinopathy, coupled with advancements in ophthalmic technology, are fueling the market growth. Other factors, such as increasing healthcare expenditure, the implementation of various government initiatives to improve eye care services, and the availability of favorable reimbursement policies, are propelling the market growth.
Diabetic retinopathy (DR) is a common complication of diabetes that affects the retina, the part of the eye that senses light and sends signals to the brain. It occurs when high blood sugar levels damage the small blood vessels in the retina, causing them to leak or become blocked. This can lead to vision loss or blindness if left untreated. There are two main types of diabetic retinopathy, namely non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Its diagnosis involves a comprehensive eye exam, which may include tests such as fluorescein angiography and optical coherence tomography. These tests can help to identify the presence and severity of DR, allowing for early intervention and treatment.
Currently, there are several treatment options available for DR, including the use of intraocular steroid injections, laser treatment, and vitrectomy. Intraocular steroid injections can help to reduce inflammation and swelling in the eye, while laser treatment can be used to seal leaking blood vessels and prevent further damage to the retina. In more severe cases, a vitrectomy may be necessary to remove blood or scar tissue from the eye.
Diabetic Retinopathy Market Trends
The global diabetic retinopathy market is witnessing significant growth, primarily driven by the rising prevalence of diabetes and the increasing geriatric population. In line with this, key players are actively working to develop new therapeutic solutions for diabetic retinopathy, which is bolstering market growth. Apart from this, the development of new drugs and therapies, such as anti-VEGF agents and sustained-release implants, has also significantly contributed to market growth. Additionally, the escalating adoption of telemedicine and artificial intelligence (AI) in the diagnosis and treatment of diabetic retinopathy is driving the market growth.The rising demand for effective treatments due to the growing awareness of diabetic retinopathy and its potential consequences is acting as another growth-inducing factor. Furthermore, the surging awareness regarding early diagnosis and treatment of diabetic retinopathy, coupled with advancements in ophthalmic technology, are fueling the market growth. Other factors, such as increasing healthcare expenditure, the implementation of various government initiatives to improve eye care services, and the availability of favorable reimbursement policies, are propelling the market growth.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global diabetic retinopathy market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on type, treatment type and end-user.Type Insights:
- Proliferative Diabetic Retinopathy
- Non-proliferative Retinopathy
Treatment Type Insights:
- Anti VEGF Drugs
- Steroid Implants
- Laser Surgeries
- Vitrectomy
End-User Insights:
- Hospitals and Pharmacies
- Eye Clinics
- Ambulatory Surgical Centres (ASCs)
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global diabetic retinopathy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
- How has the global diabetic retinopathy market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global diabetic retinopathy market?
- What is the impact of each driver, restraint, and opportunity on the global diabetic retinopathy market?
- What are the key regional markets?
- Which countries represent the most attractive diabetic retinopathy market?
- What is the breakup of the market based on the type?
- Which is the most attractive type in the diabetic retinopathy market?
- What is the breakup of the market based on the treatment type?
- Which is the most attractive treatment type in the diabetic retinopathy market?
- What is the breakup of the market based on the end-user?
- Which is the most attractive end-user in the diabetic retinopathy market?
- What is the competitive structure of the global diabetic retinopathy market?
- Who are the key players/companies in the global diabetic retinopathy market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis
2 Scope and Methodology
4 Introduction
5 Global Diabetic Retinopathy Market
6 Market Breakup by Type
7 Market Breakup by Treatment Type
8 Market Breakup by End-User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Alimera Sciences
- Allergan PLC
- Ampio Pharmaceuticals
- Bayer Healthcare
- BCN Peptides
- Genentech
- Kowa Group
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Sirnaomics Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 139 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 8.1 Billion |
| Forecasted Market Value ( USD | $ 13 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
